When GlaxoSmithKline bought out GlycoVaxyn for $190 million earlier this year, it gained a set of early-stage vaccines and commissioned GlycoVaxyn's team to create a new company around its existing research operation. That company is LimmaTech Biologics, and now, it and GSK have struck a 5-year exclusive agreement to develop novel bioconjugate antigen-based vaccines.
As researchers home in on the genetic underpinnings of disease, the National Institutes of Health (NIH) is awarding a dozen grants to scientists who are exploring ways to combine genomic test information with electronic health records to improve care for patients.
The U.K.'s National Health Service has approved the use of inVentiv Health's informed consent technology, another victory for the CRO's pioneering software.
PPD has reached out to clinical trial software provider Cisys LifeSciences to get its hands on technology the company believes can improve the process by which investigators examine and adjudicate safety events.
Clinical trial technology outfit BioClinica has created what it's calling an app exchange, looking for new software that can help physicians and drug developers through the company's cloud-based data service.
LimmaTech Biologics, a spillover from the $190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting life with GlycoVaxyn's research operation and a 5-year agreement to pump novel bioconjugate antigen‐based vaccines into GSK's pipeline.
LONDON-- Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor.
Patient monitoring company EarlySense has been on a winning streak this past year, raking in new funds and striking deals with key industry players to build out its offerings. In the company's latest move, EarlySense is bringing its technology to home settings, rolling out a product geared toward sleep and wellness monitoring.
Amgen's investigational bone-growing drug met its main goal in a late-stage trial, clearing its first Phase III hurdle by besting an Eli Lilly blockbuster for osteoporosis.
In June, Chris Martin took the helm at Spirogen spinoff ADC Therapeutics, where he's been working on a next-gen armed antibody pipeline. And he's just followed up with a whopping $80 million venture round that's designed to get the cancer company through the next three years--and possibly on into an IPO along the way.